AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.
The harmful effects of bile acid accumulation occurring during cholestatic liver diseases have been associated with oxidative stress increase and endothelial nitric oxide synthase (NOS-3) expression decrease in liver cells. We have previously reported that glycochenodeoxycholic acid (GCDCA) down-reg...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4973998?pdf=render |
id |
doaj-687823b330fb4a06aabd224c01908286 |
---|---|
record_format |
Article |
spelling |
doaj-687823b330fb4a06aabd224c019082862020-11-25T01:42:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016052510.1371/journal.pone.0160525AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression.Sandra González-RubioClara I LinaresPatricia Aguilar-MeleroManuel Rodríguez-PerálvarezJosé L Montero-ÁlvarezManuel de la MataGustavo FerrínThe harmful effects of bile acid accumulation occurring during cholestatic liver diseases have been associated with oxidative stress increase and endothelial nitric oxide synthase (NOS-3) expression decrease in liver cells. We have previously reported that glycochenodeoxycholic acid (GCDCA) down-regulates gene expression by increasing SP1 binding to the NOS-3 promoter in an oxidative stress dependent manner. In the present study, we aimed to investigate the role of transcription factor (TF) AP-1 on the NOS-3 deregulation during GCDCA-induced cholestasis. The cytotoxic response to GCDCA was characterized by 1) the increased expression and activation of TFs cJun and c-Fos; 2) a higher binding capability of these at position -666 of the NOS-3 promoter; 3) a decrease of the transcriptional activity of the promoter and the expression and activity of NOS-3; and 4) the expression increase of cyclin D1. Specific inhibition of AP-1 by the retinoid SR 11302 counteracted the cytotoxic effects induced by GCDCA while promoting NOS-3 expression recovery and cyclin D1 reduction. NOS activity inhibition by L-NAME inhibited the protective effect of SR 11302. Inducible NOS isoform was no detected in this experimental model of cholestasis. Our data provide direct evidence for the involvement of AP-1 in the NOS-3 expression regulation during cholestasis and define a critical role for NOS-3 in regulating the expression of cyclin D1 during the cell damage induced by bile acids. AP-1 appears as a potential therapeutic target in cholestatic liver diseases given its role as a transcriptional repressor of NOS-3.http://europepmc.org/articles/PMC4973998?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sandra González-Rubio Clara I Linares Patricia Aguilar-Melero Manuel Rodríguez-Perálvarez José L Montero-Álvarez Manuel de la Mata Gustavo Ferrín |
spellingShingle |
Sandra González-Rubio Clara I Linares Patricia Aguilar-Melero Manuel Rodríguez-Perálvarez José L Montero-Álvarez Manuel de la Mata Gustavo Ferrín AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. PLoS ONE |
author_facet |
Sandra González-Rubio Clara I Linares Patricia Aguilar-Melero Manuel Rodríguez-Perálvarez José L Montero-Álvarez Manuel de la Mata Gustavo Ferrín |
author_sort |
Sandra González-Rubio |
title |
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. |
title_short |
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. |
title_full |
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. |
title_fullStr |
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. |
title_full_unstemmed |
AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. |
title_sort |
ap-1 inhibition by sr 11302 protects human hepatoma hepg2 cells from bile acid-induced cytotoxicity by restoring the nos-3 expression. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
The harmful effects of bile acid accumulation occurring during cholestatic liver diseases have been associated with oxidative stress increase and endothelial nitric oxide synthase (NOS-3) expression decrease in liver cells. We have previously reported that glycochenodeoxycholic acid (GCDCA) down-regulates gene expression by increasing SP1 binding to the NOS-3 promoter in an oxidative stress dependent manner. In the present study, we aimed to investigate the role of transcription factor (TF) AP-1 on the NOS-3 deregulation during GCDCA-induced cholestasis. The cytotoxic response to GCDCA was characterized by 1) the increased expression and activation of TFs cJun and c-Fos; 2) a higher binding capability of these at position -666 of the NOS-3 promoter; 3) a decrease of the transcriptional activity of the promoter and the expression and activity of NOS-3; and 4) the expression increase of cyclin D1. Specific inhibition of AP-1 by the retinoid SR 11302 counteracted the cytotoxic effects induced by GCDCA while promoting NOS-3 expression recovery and cyclin D1 reduction. NOS activity inhibition by L-NAME inhibited the protective effect of SR 11302. Inducible NOS isoform was no detected in this experimental model of cholestasis. Our data provide direct evidence for the involvement of AP-1 in the NOS-3 expression regulation during cholestasis and define a critical role for NOS-3 in regulating the expression of cyclin D1 during the cell damage induced by bile acids. AP-1 appears as a potential therapeutic target in cholestatic liver diseases given its role as a transcriptional repressor of NOS-3. |
url |
http://europepmc.org/articles/PMC4973998?pdf=render |
work_keys_str_mv |
AT sandragonzalezrubio ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression AT clarailinares ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression AT patriciaaguilarmelero ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression AT manuelrodriguezperalvarez ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression AT joselmonteroalvarez ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression AT manueldelamata ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression AT gustavoferrin ap1inhibitionbysr11302protectshumanhepatomahepg2cellsfrombileacidinducedcytotoxicitybyrestoringthenos3expression |
_version_ |
1725037455900409856 |